Skip to content

Fars2 Deficiency Cn381326

Published: July 22, 2026Updated: August 25, 2026

A rare mitochondrial disease caused by mutations affecting mitochondrial protein synthesis. It often involves neurological problems. Treatment is primarily supportive.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
G40.909
ICD-11
8A00.0
Body system
neurologic
Severity
severe
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Seizures

Generalized symptoms

(neurologic)

Significant symptoms that substantially affect daily functioning.

Frequency: Common at all stages

Developmental delay

(neurologic)

Spasticity

(neurologic)

Movement disorder

(neurologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Ketogenic Diet Therapy

Metabolic intervention using high-fat, low-carbohydrate nutrition to bypass defective mitochondrial oxidative phosphorylation. May improve energy production and reduce lactic acidosis in some patients with mitochondrial dysfunction.

dietary
2

Medication management with follow-up

Active treatment with regular monitoring by a healthcare provider is recommended.

medication
3

Coenzyme Q10 Supplementation

Mitochondrial cofactor supplementation to support electron transport chain function and improve cellular energy production in patients with FARS2-related mitochondrial dysfunction.

medication

Additional treatment options

Comprehensive Metabolic Monitoring

Regular assessment of lactate levels, amino acid profiles, and neurological function to track disease progression and treatment response in FARS2 deficiency.

monitoring

Energy Conservation Techniques

Adaptive strategies to manage fatigue and conserve energy during daily activities, including pacing techniques and environmental modifications.

lifestyle

L-Carnitine Supplementation

Support for fatty acid oxidation and mitochondrial function through enhanced transport of fatty acids into mitochondria for energy production.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

See a doctor within 24 hours

Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.

Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Fars2 Deficiency Cn381326?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Medication Comparisons

Compare medications used to treat Fars2 Deficiency Cn381326. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy